Projects per year
Fingerprint
Dive into the research topics where Gynecologic Oncology is active. These topic labels come from the works of this organization's members. Together they form a unique fingerprint.
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Profiles
-
OSU as a Network Lead Academic Participating Site for the NCI NCTN
Verschraegen, C. (PI), Chakravarti, A. (CoPI), Carbone, D. P. (CoPI), Carson, W. E. (CoPI) & O'Malley, D. M. (CoPI)
03/28/19 → 02/28/27
Project: Research
-
OSU as Network Lead Academic Participating Site for the NCI NCTN
Verschraegen, C. (PI), Bloomfield, C. D. (CoPI), Blum, K. A. (CoPI), Byrd, J. C. (CoPI), Chakravarti, A. (CoPI), Cohn, D. (CoPI), Goldberg, R. M. (CoPI), Naughton, M. (CoPI) & Paskett, E. D. (CoPI)
05/6/14 → 02/28/19
Project: Research
-
Correction: Obesity-induced extracellular vesicles proteins drive the endometrial cancer pathogenesis: therapeutic potential of HO-3867 and Metformin (Oncogene, (2024), 43, 49, (3586-3597), 10.1038/s41388-024-03182-2)
Sakaue, T., Dorayappan, K. D. P., Zingarelli, R., Khadraoui, W., Anbalagan, M., Wallbillich, J., Bognar, B., Wanner, R., Cosgrove, C., Suarez, A., Koga, H., Maxwell, G. L., O’Malley, D. M., Cohn, D. E. & Selvendiran, K., Sep 8 2026, In: Oncogene. 45, 34, p. 3623-3626 4 p.Research output: Contribution to journal › Comment/debate
Open Access -
Exposure–Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial
Kuchimanchi, M., Jørgensen, T. L., Hanze, E., Jain, A., Alskär, O., Zub, O., Shahin, M. S., Koliadi, A., Pothuri, B., Krivak, T., Pishchyk, M., Segev, Y., Backes, F. J., Gennigens, C., Bouberhan, S., Zajic, S., Melhem, M. & Buscema, J., Aug 2026, In: Clinical Pharmacology in Drug Development. 15, 8, e70087.Research output: Contribution to journal › Article › peer-review
Open Access -
Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus (Nature Communications, (2016), 7, 1, (12675), 10.1038/ncomms12675)
GEMO Study Collaborators, EMBRACE, The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), kConFab Investigators & Australian Ovarian Cancer Study Group, Dec 2025, In: Nature Communications. 16, 1, 8237.Research output: Contribution to journal › Comment/debate
Open Access